Semaglutide on liver fibrosis and heart outcomes in patients at high risk of liver fibrosis: a prespecified analysis of the SELECT randomized trial.
Saved in:
| Title: | Semaglutide on liver fibrosis and heart outcomes in patients at high risk of liver fibrosis: a prespecified analysis of the SELECT randomized trial. |
|---|---|
| Authors: | Meyhöfer SM; Clinical, Medical & Regulatory, Novo Nordisk Pharma GmbH, Mainz, Germany. SMYF@novonordisk.com.; Department of Internal Medicine 1 - Endocrinology & Diabetes, University Medical Centre Lübeck, Lübeck, Germany. SMYF@novonordisk.com., Cariou B; Nantes Université, CHU Nantes, CNRS, INSERM, l'institut du thorax, Nantes, France., Cercato C; Obesity Unit, Department of Endocrinology, Clinical Hospital of the University of São Paulo, São Paulo, Brazil., Colhoun HM; Institute of Genetics and Cancer, The University of Edinburgh, Edinburgh, UK., Deanfield J; Institute of Cardiovascular Science, University College London, London, UK., Long MT; Novo Nordisk A/S, Søborg, Denmark.; Department of Medicine, Section of Gastroenterology, Boston University Chobanian and Avedisian School of Medicine, Boston, MA, USA., Jeppesen OK; Novo Nordisk A/S, Søborg, Denmark., Lincoff AM; Department of Cardiovascular Medicine, Cleveland Clinic and Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH, USA., Lingvay I; Department of Internal Medicine/Endocrinology and Peter O'Donnell Jr. School of Public Health, University of Texas Southwestern Medical Center, Dallas, TX, USA., Plutzky J; Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA., Newsome PN; Roger Williams Institute of Liver Studies, School of Immunology and Microbial Sciences, Faculty of Life Sciences and Medicine, King's College London, Foundation for Liver Research and King's College Hospital, London, UK., Nicholls SJ; Victorian Heart Institute, Monash University, Melbourne, Victoria, Australia., Quiroga M; Novo Nordisk A/S, Søborg, Denmark., Santini F; Obesity and Lipodystrophy Centre, University Hospital of Pisa, Pisa, Italy., Sanyal AJ; Division of Gastroenterology, Hepatology and Nutrition, Virginia Commonwealth University School of Medicine, Richmond, VA, USA., Kahn SE; Department of Medicine, VA Puget Sound Health Care System and University of Washington, Seattle, WA, USA. |
| Corporate Authors: | SELECT Trial Investigators |
| Source: | Nature medicine [Nat Med] 2026 May; Vol. 32 (5), pp. 1686-1693. Date of Electronic Publication: 2026 Apr 02. |
| Publication Type: | Journal Article; Randomized Controlled Trial |
| Journal Info: | Publisher: Nature Publishing Company Country of Publication: United States NLM ID: 9502015 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1546-170X (Electronic) Linking ISSN: 10788956 NLM ISO Abbreviation: Nat Med Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
